fda import alert glp-1 semaglutide tirzepatide green list 2025 May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations – Partnership for Safe Medicines FDA issues GLP-1 'green list,'
Description
When medication freezes, the liquid inside the vial expands
Both medications have been approved for weight management, but tirzepatide may offer additional benefits due to its dual-action mechanism
This suggests that for many people, 10 mg represents the point of diminishing returns, where side effects increase more than benefits
Patients with pre-existing cardiovascular conditions should be monitored appropriately
